ACOG
Alpha Cognition Sees Strong Growth and Progress in Q2 2026
Alpha Cognition, a leading pharmaceutical company, has announced strong growth and progress in the second quarter of 2026. The company's flagship product, ZUNVEYL, an oral Alzheimer's treatment, saw significant commercialization success during this period. According to Michael McFadden, Alpha Cognition's Chief Executive Officer, the